UA115257C2 - Фармацевтична композиція у формі твердої суміші, що містить кандесартану цилексетил та амлодипін - Google Patents
Фармацевтична композиція у формі твердої суміші, що містить кандесартану цилексетил та амлодипінInfo
- Publication number
- UA115257C2 UA115257C2 UAA201507042A UAA201507042A UA115257C2 UA 115257 C2 UA115257 C2 UA 115257C2 UA A201507042 A UAA201507042 A UA A201507042A UA A201507042 A UAA201507042 A UA A201507042A UA 115257 C2 UA115257 C2 UA 115257C2
- Authority
- UA
- Ukraine
- Prior art keywords
- candesartan cilexetil
- composition
- pharmaceutical composition
- amlodipine
- composition containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Винахід стосується комбінованої фармацевтичної композиції, у формі твердої суміші, що складається з гранульованого матеріалу, що містить кандесартану цилексетил, поліетиленгліколь та інші допоміжні засоби, де вагове співвідношення кандесартану цилексетилу та поліетиленгліколю становить 4,8:1, та позагранулярної фази, що являє собою порошкову суміш, що містить амлодипін або його фармацевтично прийнятну сіль та допоміжні засоби, способу одержання такої композиції та стандартної лікарської форми, що містить таку композицію.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL402191A PL236001B1 (pl) | 2012-12-21 | 2012-12-21 | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję |
PCT/IB2013/061138 WO2014097209A1 (en) | 2012-12-21 | 2013-12-19 | A pharmaceutical composition containing candesartan cilexetil and amlodipine |
Publications (1)
Publication Number | Publication Date |
---|---|
UA115257C2 true UA115257C2 (uk) | 2017-10-10 |
Family
ID=50030379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201507042A UA115257C2 (uk) | 2012-12-21 | 2013-12-19 | Фармацевтична композиція у формі твердої суміші, що містить кандесартану цилексетил та амлодипін |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP2934488B1 (uk) |
AU (1) | AU2013365715B2 (uk) |
BR (1) | BR112015014875A2 (uk) |
EA (1) | EA030704B1 (uk) |
ES (1) | ES2706067T3 (uk) |
HK (1) | HK1213808A1 (uk) |
HR (1) | HRP20190049T1 (uk) |
HU (1) | HUE042194T2 (uk) |
MX (1) | MX2015008032A (uk) |
MY (1) | MY185947A (uk) |
PH (1) | PH12015501301B1 (uk) |
PL (2) | PL236001B1 (uk) |
PT (1) | PT2934488T (uk) |
RS (1) | RS58214B1 (uk) |
SG (1) | SG11201504473XA (uk) |
TR (1) | TR201900350T4 (uk) |
UA (1) | UA115257C2 (uk) |
WO (1) | WO2014097209A1 (uk) |
ZA (1) | ZA201505192B (uk) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3236950B1 (en) * | 2014-12-24 | 2022-11-23 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising candesartan or pharmaceutically acceptable salts or esters thereof and amlodipine or pharmaceutically acceptable salts thereof |
CN104721159A (zh) * | 2015-03-24 | 2015-06-24 | 浙江康乐药业股份有限公司 | 一种苯磺酸氨氯地平片及其制备方法 |
KR101710441B1 (ko) * | 2015-12-28 | 2017-02-28 | 신풍제약주식회사 | 안정성 및 용출성이 향상된 정제 |
EP3219309A1 (en) * | 2016-03-17 | 2017-09-20 | K.H.S. Pharma Holding GmbH | Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension |
US10350171B2 (en) * | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
EP4374855A1 (en) * | 2022-11-22 | 2024-05-29 | KRKA, D.D., Novo Mesto | Pharmaceutical dosage form of candesartan and indapamide |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
TW284688B (uk) | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
PL189666B1 (pl) | 1998-04-09 | 2005-09-30 | Adamed Sp Z Oo | Sposób otrzymywania benzenosulfonianu amlodypiny |
HU226642B1 (en) | 2001-12-17 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Amlodipine bezylate tablets having extended stability and process for producing the same |
WO2004075825A2 (en) | 2003-02-28 | 2004-09-10 | Ranbaxy Laboratories Limited | Dosage forms of amlodipine and processes for their preparation |
WO2008065097A2 (en) | 2006-11-28 | 2008-06-05 | Laboratorios Liconsa, S.A. | Stabilized solid pharmaceutical composition of candesartan cilexetil |
JP5139515B2 (ja) | 2007-04-25 | 2013-02-06 | テバ ファーマシューティカル インダストリーズ リミティド | 医薬賦形剤複合体 |
EP2050440A1 (en) | 2007-10-18 | 2009-04-22 | Krka | Stable solid pharmaceutical composition comprising candesartan or pharmaceutically acceptable forms thereof |
EP2106789A1 (en) * | 2008-03-31 | 2009-10-07 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising candesartan |
DK2165702T3 (da) | 2008-09-17 | 2012-03-05 | Helm Ag | Stabile og let opløselige sammensætninger af candesartancilexetil fremstillet ved vådgranulering |
NZ596395A (en) | 2009-04-30 | 2013-06-28 | Takeda Pharmaceutical | Stable solid benzimidazole derivative preparation having optimized dissolution property |
CN101966181A (zh) * | 2010-07-08 | 2011-02-09 | 王丽燕 | 包含坎地沙坦和氨氯地平的口服固体制剂及其新应用 |
CN102743381B (zh) * | 2011-04-22 | 2014-08-27 | 重庆市力扬医药开发有限公司 | 一种稳定的坎地沙坦酯氨氯地平药物组合物及其制备方法 |
CN102764258B (zh) | 2011-10-21 | 2013-09-25 | 四川百利药业有限责任公司 | 一种坎地沙坦酯氨氯地平复方片的制备方法 |
CN102670603B (zh) * | 2012-04-29 | 2017-10-31 | 浙江华海药业股份有限公司 | 含有坎地沙坦酯和苯磺酸氨氯地平的口服片剂及其制备方法 |
CN102688236B (zh) * | 2012-06-06 | 2014-03-26 | 石药集团中诺药业(石家庄)有限公司 | 一种坎地沙坦酯氨氯地平片剂组合物及其制备方法 |
-
2012
- 2012-12-21 PL PL402191A patent/PL236001B1/pl unknown
-
2013
- 2013-12-19 TR TR2019/00350T patent/TR201900350T4/tr unknown
- 2013-12-19 SG SG11201504473XA patent/SG11201504473XA/en unknown
- 2013-12-19 WO PCT/IB2013/061138 patent/WO2014097209A1/en active Application Filing
- 2013-12-19 EA EA201591097A patent/EA030704B1/ru unknown
- 2013-12-19 ES ES13826632T patent/ES2706067T3/es active Active
- 2013-12-19 EP EP13826632.5A patent/EP2934488B1/en active Active
- 2013-12-19 PT PT13826632T patent/PT2934488T/pt unknown
- 2013-12-19 UA UAA201507042A patent/UA115257C2/uk unknown
- 2013-12-19 MY MYPI2015001480A patent/MY185947A/en unknown
- 2013-12-19 BR BR112015014875A patent/BR112015014875A2/pt active Search and Examination
- 2013-12-19 HU HUE13826632A patent/HUE042194T2/hu unknown
- 2013-12-19 MX MX2015008032A patent/MX2015008032A/es active IP Right Grant
- 2013-12-19 AU AU2013365715A patent/AU2013365715B2/en active Active
- 2013-12-19 RS RS20190047A patent/RS58214B1/sr unknown
- 2013-12-19 PL PL13826632T patent/PL2934488T3/pl unknown
-
2015
- 2015-06-08 PH PH12015501301A patent/PH12015501301B1/en unknown
- 2015-07-20 ZA ZA2015/05192A patent/ZA201505192B/en unknown
-
2016
- 2016-02-19 HK HK16101894.7A patent/HK1213808A1/zh unknown
-
2019
- 2019-01-08 HR HRP20190049TT patent/HRP20190049T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
HUE042194T2 (hu) | 2019-06-28 |
RS58214B1 (sr) | 2019-03-29 |
ES2706067T3 (es) | 2019-03-27 |
AU2013365715B2 (en) | 2017-10-05 |
PH12015501301A1 (en) | 2015-08-24 |
MY185947A (en) | 2021-06-14 |
HK1213808A1 (zh) | 2016-07-15 |
BR112015014875A2 (pt) | 2017-07-11 |
EA201591097A1 (ru) | 2015-10-30 |
PL236001B1 (pl) | 2020-11-30 |
EP2934488A1 (en) | 2015-10-28 |
PH12015501301B1 (en) | 2015-08-24 |
PT2934488T (pt) | 2019-01-29 |
TR201900350T4 (tr) | 2019-02-21 |
HRP20190049T1 (hr) | 2019-02-22 |
PL402191A1 (pl) | 2014-06-23 |
AU2013365715A1 (en) | 2015-06-18 |
SG11201504473XA (en) | 2015-07-30 |
EP2934488B1 (en) | 2018-10-17 |
ZA201505192B (en) | 2016-07-27 |
WO2014097209A1 (en) | 2014-06-26 |
PL2934488T3 (pl) | 2019-04-30 |
EA030704B1 (ru) | 2018-09-28 |
MX2015008032A (es) | 2015-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501301A1 (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
WO2012143576A3 (en) | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) | |
GB2495676A (en) | Use of binders for manufacturing storage stable formulations | |
NZ602442A (en) | A fast dissolving pharmaceutical composition | |
IN2014MN01919A (uk) | ||
IL231170A (en) | Nitrate mustard derivative compound, pharmaceutical preparation, use of drug preparation and compound for use as a drug | |
MX340188B (es) | Elaboracion de granulos sin activos y tabletas que comprenden los mismos. | |
TN2011000651A1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application | |
SI2729130T1 (en) | Combined formulations of darunavir | |
MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
MX2016003754A (es) | Una composicion farmaceutica estable que contiene amlodipina y valsartan. | |
IL227024A (en) | The 3 heteroarylamino propionic acid derivatives are converted into amino acids, a process for their preparation, their use in the preparation of medicinal preparations and as medical preparations containing them | |
HRP20180316T1 (hr) | Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala | |
PH12014502619A1 (en) | Novel dosage and formulation | |
IL225105A (en) | Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs | |
EP2551266A4 (en) | NON-NUCLEOSIDE 2 ', 2-DITHIAZOLE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES AS HEPATITIS VIRUS INHIBITORS | |
TN2012000363A1 (en) | Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation | |
EP2871187A4 (en) | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | |
EP2497464A3 (en) | Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture | |
EA033291B1 (ru) | Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии | |
WO2011108882A3 (ko) | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 | |
EP2842938A4 (en) | NOVEL BETA-ALANINE DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | |
HRP20171930T1 (hr) | Analozi diazonamida | |
WO2011126327A3 (en) | Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof |